Search Results

There are 3176 results for: content related to: Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

  1. Bisphosphonates and other bone agents for breast cancer

    Intervention Review

    The Cochrane Library

    Matthew HF Wong, Martin R Stockler and Nick Pavlakis

    Published Online : 15 FEB 2012, DOI: 10.1002/14651858.CD003474.pub3

  2. You have free access to this content
    Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model

    International Journal of Cancer

    Volume 126, Issue 2, 15 January 2010, Pages: 522–532, Penelope D. Ottewell, Diane V. Lefley, Simon S. Cross, C. Alyson Evans, Robert E. Coleman and Ingunn Holen

    Version of Record online : 20 JUL 2009, DOI: 10.1002/ijc.24756

  3. You have full text access to this Open Access content
    The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells

    Journal of Cellular and Molecular Medicine

    Volume 15, Issue 3, March 2011, Pages: 501–513, Hannah K. Brown, Penelope D. Ottewell, Robert E. Coleman and Ingunn Holen

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00995.x

  4. You have free access to this content
    Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma


    Volume 104, Issue 8, 15 October 2005, Pages: 1713–1720, Zhichao Zhou, Hui Guan, Xiaoping Duan and Eugenie S. Kleinerman

    Version of Record online : 24 AUG 2005, DOI: 10.1002/cncr.21383

  5. You have free access to this content
    Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis

    BJU International

    Volume 109, Issue 3, February 2012, Pages: 394–400, Kouji Izumi, Atsushi Mizokami, Shingo Itai, Takashi Shima, Kazuyoshi Shigehara, Sotaro Miwa, Yuji Maeda, Hiroyuki Konaka, Eitetsu Koh and Mikio Namiki

    Version of Record online : 23 MAY 2011, DOI: 10.1111/j.1464-410X.2011.10192.x

  6. You have free access to this content
    Final 5-year results of Z-FAST trial


    Volume 118, Issue 5, 1 March 2012, Pages: 1192–1201, Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson and Edith A. Perez

    Version of Record online : 10 OCT 2011, DOI: 10.1002/cncr.26313

  7. You have free access to this content
    Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases


    Volume 91, Issue 7, 1 April 2001, Pages: 1191–1200, James R. Berenson, Lee S. Rosen, Anthony Howell, Lester Porter, Robert E. Coleman, Walter Morley, Robert Dreicer, Steven A. Kuross, Allan Lipton and John J. Seaman

    Version of Record online : 27 MAR 2001, DOI: 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0

  8. You have free access to this content
    Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival

    Journal of Bone and Mineral Research

    Volume 18, Issue 3, March 2003, Pages: 482–492, Peter I Croucher, Hendrik De Raeve, Mark J Perry, Anja Hijzen, Claire M Shipman, Jennifer Lippitt, Jonathan Green, Eric Van Marck, Ben Van Camp and Karin Vanderkerken

    Version of Record online : 1 MAR 2003, DOI: 10.1359/jbmr.2003.18.3.482

  9. You have free access to this content
    Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

    International Journal of Cancer

    Volume 113, Issue 3, 20 January 2005, Pages: 364–371, Helen L. Neville-Webbe, Amin Rostami-Hodjegan, Catherine A. Evans, Robert E. Coleman and Ingunn Holen

    Version of Record online : 28 SEP 2004, DOI: 10.1002/ijc.20602

  10. Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements

    Journal of Cardiovascular Electrophysiology


    Version of Record online : 31 MAR 2015, DOI: 10.1111/jce.12641

  11. The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function

    The Journal of Clinical Pharmacology

    Volume 43, Issue 2, February 2003, Pages: 154–162, Dr. Andrej Skerjanec, Dr. James Berenson, Dr. ChyiHung Hsu, Dr. Pierre Major, Dr. Wilson H. Miller Jr., Ms. Christina Ravera, Dr. Horst Schran, Dr. John Seaman and Dr. Felix Waldmeier

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270002239824

  12. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

    Cell Biology International

    Volume 33, Issue 2, February 2009, Pages: 239–246, B. Karabulut, C. Erten, M.K. Gul, E. Cengiz, B. Karaca, Y. Kucukzeybek, G. Gorumlu, H. Atmaca, S. Uzunoglu, U.A. Sanli, Y. Baran and R. Uslu

    Version of Record online : 2 JAN 2013, DOI: 10.1016/j.cellbi.2008.11.011

  13. Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis from Solid Tumor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 3, March 2012, Pages: 274–284, Maryam Iranikhah, Teresa W. Wilborn, Terri M. Wensel and Jodi B. Ferrell

    Version of Record online : 13 FEB 2012, DOI: 10.1002/j.1875-9114.2011.01092.x

  14. You have free access to this content
    The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid


    Volume 109, Issue 6, 15 March 2007, Pages: 1090–1096, William K. Oh, Kevin Proctor, Mari Nakabayashi, Carolyn Evan, Lauren K. Tormey, Timothy Daskivich, Lucia Antràs, Michael Smith, Maureen P. Neary and Mei Sheng Duh

    Version of Record online : 20 FEB 2007, DOI: 10.1002/cncr.22504

  15. You have free access to this content
    A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

    Journal of Bone and Mineral Research

    Volume 26, Issue 9, September 2011, Pages: 2261–2270, Ian R Reid, Kenneth Lyles, Guoqin Su, Jacques P Brown, John P Walsh, Javier del Pino-Montes, Paul D Miller, William D Fraser, Susan Cafoncelli, Christina Bucci-Rechtweg and David J Hosking

    Version of Record online : 19 AUG 2011, DOI: 10.1002/jbmr.438

  16. You have free access to this content
    Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma


    Volume 98, Issue 5, 1 September 2003, Pages: 962–969, Allan Lipton, Ming Zheng and John Seaman

    Version of Record online : 26 JUN 2003, DOI: 10.1002/cncr.11571

  17. You have free access to this content
    Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors


    Volume 100, Issue 12, 15 June 2004, Pages: 2613–2621, Lee S. Rosen, David Gordon, N. Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, Maciej Krzakowski, Marek Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk Reitsma, John Seaman and On behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

    Version of Record online : 6 MAY 2004, DOI: 10.1002/cncr.20308

  18. You have free access to this content
    A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease


    Volume 91, Issue 1, 1 January 2001, Pages: 144–154, James R. Berenson, Robert Vescio, Kathryn Henick, Carol Nishikubo, Matthew Rettig, Regina A. Swift, Francisco Conde and Joseph M. Von Teichert

    Version of Record online : 4 JAN 2001, DOI: 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q

  19. You have free access to this content
    Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure

    Journal of Bone and Mineral Research

    Volume 23, Issue 1, January 2008, Pages: 6–16, Robert R Recker, Pierre D Delmas, Johan Halse, Ian R Reid, Steven Boonen, Pedro A García-Hernandez, Jerzy Supronik, E Michael Lewiecki, Luis Ochoa, Paul Miller, Huilin Hu, Peter Mesenbrink, Florian Hartl, Juerg Gasser and Erik F Eriksen

    Version of Record online : 10 SEP 2007, DOI: 10.1359/jbmr.070906

  20. You have free access to this content
    Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial

    Journal of Bone and Mineral Research

    Volume 26, Issue 5, May 2011, Pages: 984–992, Jane A Cauley, Dennis Black, Steven Boonen, Steven R Cummings, Peter Mesenbrink, Lisa Palermo, Zulema Man, Peyman Hadji, Ian R Reid and on behalf of the HORIZON Pivotal Fracture Group

    Version of Record online : 3 MAY 2011, DOI: 10.1002/jbmr.292